canyon landscape

LY3154207 in Participants With Dementia due to Lewy Body Dementia

A randomized placebo-controlled trial to evaluate the safety and efficacy of three doses of study drug LY3154207 treated for 12 weeks in participants with mild-to-moderate dementia associated with LBD (PDD or DLB).
Open and enrolling subjects.
Phoenix, Arizona
Age Range
  • 40-85
Total Participants
Primary Sponsor
Eli Lilly and Company